Biocon Ltd

BIOCON
Health CareBiotechnology
MidcapWith a market cap of ₹40,332 cr, stock is ranked 113
Moderate RiskStock is 2.03x as volatile as Nifty
329.408.65 (-2.56%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareBiotechnology
MidcapWith a market cap of ₹40,332 cr, stock is ranked 113
Moderate RiskStock is 2.03x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
62.20
PB RatioPB Ratio
4.74
Dividend YieldDiv. Yield
0.15%
Sector PESector PE
32.23
Sector PBSector PB
4.77
Sector Div YldSctr Div Yld
0.86%

Forecast & RatingsDetailed Forecast 

55%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.

Brands

Biocon

Biotech company

Investor PresentationView older 

Apr 29, 2022

PDF
View Older Presentations

Brands

Biocon

Biotech company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

20192020202120225.856.537.378.400.910.750.740.65
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Schedule of Analysts/Institutional Investor Meet/Con. Call 
Announced OnMay 24, 2022

Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call | Download

Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call | Download

Press Release 
Announced OnMay 19, 2022

Biocon Limited has informed the Exchange about press release dated 19-May-2022 titled "Biocon Biologics and Viatris Launch Abevmyᅡᆴ (bBevacizumab), Their Third Oncology Biosimilar, in Canada" | Download

Biocon Limited has informed the Exchange about press release dated 19-May-2022 titled "Biocon Biologics and Viatris Launch Abevmyᅡᆴ (bBevacizumab), Their Third Oncology Biosimilar, in Canada" | Download

Cash Dividend 
Ex. DateJul 18, 2019

Final • Div/Share: ₹ 0.5

See all events